Concerted Actions by PIICP, CTXII, and TNF-α in Patients with Juvenile Idiopathic Arthritis.
Antirheumatic Agents
/ therapeutic use
Arthritis, Juvenile
/ metabolism
Biomarkers, Pharmacological
/ blood
Blood Sedimentation
C-Reactive Protein
/ analysis
Child
Child, Preschool
Collagen Type I
/ analysis
Collagen Type II
/ metabolism
Female
Humans
Male
Peptide Fragments
/ analysis
Peptides
/ analysis
Procollagen
/ analysis
Tumor Necrosis Factor-alpha
/ analysis
C-telopeptide of type II collagen
cartilage turnover markers
juvenile idiopathic arthritis
procollagen II C-terminal propeptide
tumor necrosis factor-α
Journal
Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414
Informations de publication
Date de publication:
28 04 2021
28 04 2021
Historique:
received:
06
04
2021
revised:
22
04
2021
accepted:
27
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
23
9
2021
Statut:
epublish
Résumé
Joint destruction in juvenile idiopathic arthritis (JIA), initiated in the early, preclinical stage of the disease, is diagnosed on the basis of clinical evaluation and radiographic imaging. The determination of circulating cartilage-matrix turnover markers can facilitate the diagnosis and application of better and earlier treatment strategies for JIA. We have shown that 96 JIA patients have elevated levels of procollagen II C-terminal propeptide (PIICP), reflecting the extent of joint cartilage biosynthesis, and C-telopeptide of type II collagen (CTXII), a biomarker of the resorption of this tissue. Patients who did not respond to treatment had particularly high levels of these markers. JIA treatment resulted in the normalization of these markers in remissive patients, but not in those with active JIA. We showed correlations between examined variables and inflammatory process indicators, i.e., C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and tumor necrosis factor-α (TNF-α). The TNF-α of patients responding to treatment correlated with PIICP, especially in the patients before treatment (r = 0.898,
Identifiants
pubmed: 33924892
pii: biom11050648
doi: 10.3390/biom11050648
pmc: PMC8146247
pii:
doi:
Substances chimiques
Antirheumatic Agents
0
Biomarkers, Pharmacological
0
Collagen Type I
0
Collagen Type II
0
Peptide Fragments
0
Peptides
0
Procollagen
0
Tumor Necrosis Factor-alpha
0
collagen type I trimeric cross-linked peptide
0
procollagen type II carboxy-terminal peptide
0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Śląski Uniwersytet Medyczny
ID : PCN-1-020/N/0/I
Références
Int J Mol Sci. 2017 Apr 25;18(5):
pubmed: 28441353
J Rheumatol. 2019 Feb;46(2):190-197
pubmed: 30275259
J Rheumatol. 2008 Feb;35(2):310-4
pubmed: 18203315
Clin Exp Pharmacol Physiol. 2008 Jul;35(7):846-51
pubmed: 18215180
J Immunol Res. 2018 Nov 28;2018:3856897
pubmed: 30622975
Adv Clin Exp Med. 2018 Mar;27(3):383-389
pubmed: 29533545
J Biol Chem. 2013 Mar 29;288(13):8785-93
pubmed: 23430258
Matrix Biol. 2015 May-Jul;44-46:224-31
pubmed: 25599938
Postepy Hig Med Dosw (Online). 2016 Mar 04;70:135-42
pubmed: 26943311
Pediatr Rheumatol Online J. 2014 Jun 11;12:22
pubmed: 24944545
Arthritis Res Ther. 2016 Apr 01;18:81
pubmed: 27039382
Arthritis Res Ther. 2010;12(6):R229
pubmed: 21194441
J Rheumatol. 2004 Feb;31(2):390-2
pubmed: 14760812
Assay Drug Dev Technol. 2013 Mar;11(2):70-92
pubmed: 23046407
Clin Exp Rheumatol. 2020 Mar-Apr;38(2):355-365
pubmed: 31694747
J Immunol. 2003 Oct 1;171(7):3855-62
pubmed: 14500687
Clin Biochem. 2014 Jun;47(9):829-34
pubmed: 24495859
Metabolites. 2020 Feb 10;10(2):
pubmed: 32050571
Rheumatol Int. 2018 Mar;38(3):455-459
pubmed: 29396701
Postepy Hig Med Dosw (Online). 2016 Jul 06;70(0):743-50
pubmed: 27383571
Ann Rheum Dis. 2003 Jan;62(1):27-32
pubmed: 12480665
Ann Rheum Dis. 2002 Nov;61 Suppl 2:ii78-81
pubmed: 12379630
Int J Mol Sci. 2018 Nov 06;19(11):
pubmed: 30404167
FEBS J. 2019 Aug;286(15):2830-2869
pubmed: 30908868
Prog Mol Biol Transl Sci. 2017;147:1-73
pubmed: 28413025
Pharmacotherapy. 2017 Jun;37(6):700-711
pubmed: 28475276
J Hepatol. 2016 Jan;64(1):103-9
pubmed: 26307398
Biochim Biophys Acta. 2012 Jan;1824(1):133-45
pubmed: 21777704
J Funct Morphol Kinesiol. 2019 Aug 19;4(3):
pubmed: 33467373
Ann Rheum Dis. 2006 Apr;65(4):501-7
pubmed: 16150790
Arthritis Rheum. 2003 Nov;48(11):3085-95
pubmed: 14613270
Exp Ther Med. 2016 Sep;12(3):1481-1489
pubmed: 27588069
Vestn Ross Akad Med Nauk. 2013;(7):36-40
pubmed: 24340960
J Rheumatol. 1996 Oct;23(10):1765-9
pubmed: 8895155
Sci Rep. 2019 Feb 28;9(1):3050
pubmed: 30816326
Clin Chim Acta. 2006 Mar;365(1-2):68-77
pubmed: 16257399
Clin Lab. 2014;60(5):799-807
pubmed: 24839823
Oxid Med Cell Longev. 2017;2017:5601593
pubmed: 28392887
Scand J Rheumatol. 2017 May;46(3):194-197
pubmed: 27385219
Biomed Res Int. 2019 Oct 28;2019:7420345
pubmed: 31781639
Rheumatology (Oxford). 2002 Jun;41(6):691-6
pubmed: 12048298
Clin Exp Rheumatol. 2016 Nov-Dec;34(6):991-998
pubmed: 27749237
Balkan Med J. 2017 Apr 5;34(2):90-101
pubmed: 28418334
Osteoarthritis Cartilage. 2017 Sep;25(9):1420-1427
pubmed: 28433814
Ann Rheum Dis. 2018 Jun;77(6):819-828
pubmed: 29643108
Arthritis Care Res (Hoboken). 2016 Dec;68(12):1795-1802
pubmed: 27110936
Clin Chem Lab Med. 2015 Feb;53(2):291-7
pubmed: 25153398
Int J Rheum Dis. 2019 Jul;22(7):1263-1270
pubmed: 31117159
J Clin Invest. 1995 Mar;95(3):1071-7
pubmed: 7533784
Protein Cell. 2017 Aug;8(8):560-572
pubmed: 28213717
Osteoarthritis Cartilage. 2006 Apr;14(4):345-52
pubmed: 16311048
J Rheumatol. 2011 Nov;38(11):2482-7
pubmed: 21885500
Immunol Lett. 2015 May;165(1):20-5
pubmed: 25800643
Pathobiology. 2009;76(5):260-6
pubmed: 19816086